These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 25432018)

  • 21. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
    Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
    Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
    Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
    BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
    Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
    J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis.
    Stoll G; Surdez D; Tirode F; Laud K; Barillot E; Zinovyev A; Delattre O
    Nucleic Acids Res; 2013 Oct; 41(19):8853-71. PubMed ID: 23935076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.
    Yang L; Hu HM; Zielinska-Kwiatkowska A; Chansky HA
    Biochem Biophys Res Commun; 2010 Nov; 402(1):129-34. PubMed ID: 20933505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
    Kinsey M; Smith R; Lessnick SL
    Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
    Kovar H
    Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.
    Selvanathan SP; Graham GT; Erkizan HV; Dirksen U; Natarajan TG; Dakic A; Yu S; Liu X; Paulsen MT; Ljungman ME; Wu CH; Lawlor ER; Üren A; Toretsky JA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1307-16. PubMed ID: 25737553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
    Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
    J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
    Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1.
    Barber-Rotenberg JS; Selvanathan SP; Kong Y; Erkizan HV; Snyder TM; Hong SP; Kobs CL; South NL; Summer S; Monroe PJ; Chruszcz M; Dobrev V; Tosso PN; Scher LJ; Minor W; Brown ML; Metallo SJ; Üren A; Toretsky JA
    Oncotarget; 2012 Feb; 3(2):172-82. PubMed ID: 22383402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.
    Grohar PJ; Kim S; Rangel Rivera GO; Sen N; Haddock S; Harlow ML; Maloney NK; Zhu J; O'Neill M; Jones TL; Huppi K; Grandin M; Gehlhaus K; Klumpp-Thomas CA; Buehler E; Helman LJ; Martin SE; Caplen NJ
    Cell Rep; 2016 Jan; 14(3):598-610. PubMed ID: 26776507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A polypeptide from the junction region sequence of EWS-FLI1 inhibits Ewing's sarcoma cells, interacts with the EWS-FLI1 and partner proteins.
    Thangaretnam KP; Gopisetty G; Ramanathan P; Rajkumar T
    Sci Rep; 2017 Aug; 7(1):7172. PubMed ID: 28775288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors.
    Erkizan HV; Scher LJ; Gamble SE; Barber-Rotenberg JS; Sajwan KP; Üren A; Toretsky JA
    Cell Cycle; 2011 Oct; 10(19):3397-408. PubMed ID: 21926473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner.
    Harlow ML; Chasse MH; Boguslawski EA; Sorensen KM; Gedminas JM; Kitchen-Goosen SM; Rothbart SB; Taslim C; Lessnick SL; Peck AS; Madaj ZB; Bowman MJ; Grohar PJ
    Clin Cancer Res; 2019 Jun; 25(11):3417-3429. PubMed ID: 30723142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EWS/FLI1 suppresses retinoblastoma protein function and senescence in Ewing's sarcoma cells.
    Hu HM; Zielinska-Kwiatkowska A; Munro K; Wilcox J; Wu DY; Yang L; Chansky HA
    J Orthop Res; 2008 Jun; 26(6):886-93. PubMed ID: 18271016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for DAX1/EWS-FLI1 functional inhibitors identified dihydroorotate dehydrogenase as a therapeutic target for Ewing's sarcoma.
    Watanabe M; Kosaka H; Sugawara M; Maemoto M; Ono Y; Uemori T; Shizu R; Yoshinari K
    Cancer Med; 2023 Apr; 12(8):9802-9814. PubMed ID: 36825574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A.
    Toretsky JA; Erkizan V; Levenson A; Abaan OD; Parvin JD; Cripe TP; Rice AM; Lee SB; Uren A
    Cancer Res; 2006 Jun; 66(11):5574-81. PubMed ID: 16740692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.
    Uren A; Toretsky JA
    Future Oncol; 2005 Aug; 1(4):521-8. PubMed ID: 16556028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
    Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
    PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.